SABCS 2021

Hypothesis-generating study in the HER2-enriched…

Benefit only related to chemotherapy?!

Metformin is not an anti-cancer drug

Critical consideration of the study data is necessary

Genomic signatures of DCIS

The next standard for TNBC?!

Re-evaluation confirms old data

The risk-adapted decision for or against AI has to be…

Metformin shows no efficacy for most cancer patients

Negative results with hope for translational projects

Molecular-guided treatment is of value in combination…

Leading the way for other ct-DNA trials

Solved and unsolved controversies of early breast…

Muss die risiko-adaptierte Entscheidungsfindung bei AI…

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

"Signatures Genomiche " nel carcinoma duttale in situ

Hypothesen-generierende Studie beim HER2-enriched…

La metformina non può essere considerata un farmaco…

Kritische Betrachtung der Studiendaten notwendig

E’ solo effetto della chemioterapia?

Erneute Auswertung bestätigt alte Daten

KEYNOTE-522 confirms ICI benefit in the neoadjuvant…

RxPONDER: Benefit only for pre-menopausal patients?…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

TNBC EBC: What is the new neoadjuvant standard…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

Final results of the CPS score subgroup analyses show…

Exciting novel therapies for metastatic TNBC

Oral SERDs for early setting and adjuvant therapy

Best of the year: systemic therapy

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Reconfirming effect of T-DXd in patients with brain…

T-Dxd is also active in patients with brain metastasis

More good news for TDXd

Very good news for endocrine resistant metastatic…

Dato-Dxd for metastatic TNBC

Imaging with mass cytometry can provide predictive…

Switching with molecular progress improves PFS

Effectiveness depending on PDL1 status

Activity of T-Dxd across all Her2-expressing breast…

Immuntherapy for high tumor mutation burden in…

My highlights of 2021 in metastatic breast cancer

TROP2 - new target for improved chemotherapy

Samuraciclib - new targeted therapy for luminal breast…

TDXd is very efficient in patients with brain…

Oral SERDs are efficient, but show high progression…

Promising results for TNBC patients

IO + IO without resounding success in the mBC setting

Pioneering study of personalized medicine in advanced…

Which patients will benefit from Pembro in metastatic…

Dato-DXd new promising ADC

Amazing period for patients with refractory metastatic…

Precision oncology is beneficial in certain mBC…

3 updates - 3 new standards of care

Chekpoint inhibition in breast cancer

Pooled analyses shows OS benefit for most subgroups

Robust benefit of pembroluzimab in addition to…

Elacestrant - less than we expected

Umstellung bei molekularem Progress verlängert PFS

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

Important benefice de l’ajout du pembrolizumab à la…

È un grande momento per i pazienti con tumore mammario…

Elacestrant – poniżej oczekiwań

Wirksamkeit in Abhängigkeit von PDL1-Stautus

Mi retrospectiva del cáncer de mama metastático en 2021

Buone notizie per i tumori mammari endocrino resistenti

Résultats prometteurs dans le cancer du sein triple…

Checkpoint-Inhibition beim Mammakarzinom

Risultati promettenti nel tumore al seno triplo…

Präzisionsonkologie funktioniert beim mBC

IO + IO ohne durchschlagenden Erfolg beim mBC

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Best of the Year: Systemtherapie

Werden orale SERDs die Therapie mit Fulvestrant in…

Samuracyklib – nowe leczenie celowane w rakach…

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Wegweisende Daten für die personalisierte Medizin beim…

L’imaging mass cytometry può aiutare a predire…

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Amélioration de la survie sans progression par le…

Resultados finales de los análisis de los subgrupos de…

Neues Target für optimierte Chemotherapie

T-Dxd aktywny również w przerzutach do mózgu

Activité du T-DXd dans les metastases cérébrales

Integrating patients perspectives in metastatic breast…

MBC TNBC: Molecular tumor characteristics define the…

MBC HR+: What is the best option after a CDK4/6i…

Are SERDs a future therapy for endocrine resistant…

Therapy of brain metastasis – can T-DXd be the new SoC?

Targeting rare mutations in breast cancer - is this the…

New ADCs on the horizon for TNBC patients